Novo Nordisk PE Ratio 2010-2022 | NVO

Current and historical p/e ratio for Novo Nordisk (NVO) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Novo Nordisk PE ratio as of February 03, 2023 is 39.42.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Novo Nordisk PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-02-06 138.07 52.30
2022-12-31 135.34 $2.64 51.27
2022-09-30 99.63 $3.37 29.56
2022-06-30 110.83 $3.35 33.08
2022-03-31 110.45 $3.36 32.87
2021-12-31 110.34 $3.30 33.44
2021-09-30 94.58 $3.21 29.47
2021-06-30 82.09 $3.06 26.83
2021-03-31 66.07 $2.88 22.94
2020-12-31 67.53 $2.75 24.56
2020-09-30 67.12 $2.66 25.23
2020-06-30 62.81 $2.61 24.06
2020-03-31 57.74 $2.55 22.65
2019-12-31 54.76 $2.46 22.26
2019-09-30 48.92 $2.45 19.97
2019-06-30 47.88 $2.39 20.03
2019-03-31 49.07 $2.46 19.95
2018-12-31 43.21 $2.53 17.08
2018-09-30 44.22 $2.52 17.55
2018-06-30 42.84 $2.56 16.74
2018-03-31 45.75 $2.47 18.52
2017-12-31 49.04 $2.32 21.14
2017-09-30 44.00 $2.29 19.21
2017-06-30 38.79 $2.25 17.24
2017-03-31 31.00 $2.26 13.72
2016-12-31 31.79 $2.23 14.25
2016-09-30 36.87 $2.20 16.76
2016-06-30 47.21 $2.11 22.37
2016-03-31 47.57 $1.99 23.90
2015-12-31 50.10 $2.01 24.93
2015-09-30 46.79 $1.92 24.37
2015-06-30 47.24 $1.85 25.54
2015-03-31 46.06 $1.85 24.90
2014-12-31 35.96 $1.73 20.79
2014-09-30 40.47 $1.77 22.86
2014-06-30 39.25 $1.79 21.93
2014-03-31 38.79 $1.76 22.07
2013-12-31 30.82 $1.69 18.19
2013-09-30 28.23 $1.66 17.02
2013-06-30 25.85 $1.58 16.38
2013-03-31 26.94 $1.45 18.58
2012-12-31 26.70 $1.36 19.63
2012-09-30 25.81 $1.25 20.62
2012-06-30 23.77 $1.17 20.29
2011-12-31 18.53 $1.11 16.69
2011-09-30 16.00 $1.07 15.01
2011-06-30 20.14 $1.02 19.74
2011-03-31 20.13 $0.95 21.14
2010-12-31 17.83 $0.99 18.01
2010-09-30 15.59 $0.94 16.62
2010-06-30 12.83 $0.86 14.85
2012-03-31 22.69 $0.83 27.21
2010-03-31 12.22 $0.72 17.01
2009-12-31 9.94 $0.67 14.74
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $309.551B $25.059B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $430.370B 16.20
Eli Lilly (LLY) United States $322.186B 42.71
Merck (MRK) United States $260.994B 13.76
AbbVie (ABBV) United States $256.783B 10.65
Pfizer (PFE) United States $247.323B 6.70
Novartis AG (NVS) Switzerland $189.952B 14.05